BioCryst Pharmaceuticals financials
$8.27−2.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $874.8M | $450.7M | $331.4M | $270.8M | $157.2M | $17.8M | $48.8M | $20.7M | $25.2M | $26.4M |
| Gross profit | $855.8M | $438.4M | $326.9M | $264.4M | $149.9M | $16.3M | $45.1M | $20.7M | $24.0M | $24.1M |
| Gross margin | 97.8% | 97.3% | 98.6% | 97.6% | 95.4% | 91.3% | 92.4% | 100.0% | 95.5% | 91.3% |
| Operating income | $341.0M | -$2.5M | -$103.7M | -$148.4M | -$177.7M | -$174.8M | -$99.5M | -$94.2M | -$57.4M | -$48.6M |
| Net income | $263.9M | -$88.9M | -$226.5M | -$247.1M | -$184.1M | -$182.8M | -$108.9M | -$101.3M | -$65.8M | -$55.1M |
| Net margin | 30.2% | −19.7% | −68.4% | −91.2% | −117.1% | −1026.4% | −223.0% | −490.3% | −261.2% | −209.3% |
| Diluted EPS | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-0.94 | $-0.98 | $-0.78 | $-0.75 |
| EBITDA | $342.4M | -$1.3M | -$102.1M | -$147.0M | -$176.9M | -$174.0M | -$98.7M | -$93.5M | -$56.7M | -$48.1M |
| Operating cash flow | $347.4M | -$52.0M | -$95.1M | -$161.8M | -$142.2M | -$135.1M | -$89.6M | -$92.6M | -$41.1M | -$53.4M |
| Free cash flow | $344.9M | -$53.1M | -$97.3M | -$163.2M | -$144.5M | -$135.6M | -$89.9M | -$92.9M | -$41.5M | -$58.7M |
| Diluted shares | 218.6M | 206.7M | 192.2M | 185.9M | 179.1M | 167.3M | 115.6M | 103.2M | 84.5M | 73.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $89.7M | $104.7M | $110.6M | $304.8M | $504.4M | $272.1M |
| Short-term investments | $185.0M | $216.1M | $278.3M | $119.5M | $3.2M | $28.2M |
| Total debt | $468.4M | $832.6M | $839.3M | $234.3M | $136.1M | $171.4M |
| Total assets | $514.2M | $490.4M | $517.0M | $550.0M | $588.2M | $334.7M |
| Total liabilities | $633.3M | $966.4M | $972.5M | $844.6M | $695.1M | $354.0M |
| Shareholders' equity | -$119.2M | -$475.9M | -$455.5M | -$294.6M | -$107.0M | -$19.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology